614-864-4919 info@sermonixpharma.com
  • Facebook
  • Twitter
  • RSS
  • Facebook
  • Twitter
  • RSS
Sermonix Pharmaceuticals
  • About
    • Company Overview
    • Management Team
    • Board of Directors
    • Oncology Steering Committee
    • Partners & Collaborations
  • Breast Cancer
  • Pipeline
    • Pipeline
    • Lasofoxifene
  • ELAINE Studies
    • The ELAINE-1 Study
    • The ELAINE-2 Study
    • EQUALS
  • News & Media
    • News
    • Media
  • Posters & Presentations
  • Contact
Select Page

jar

by Max Sevostianov | Dec 31, 2019 | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts

  • Sermonix Pharmaceuticals Shares Encore ELAINE-2 Poster Presentation at 2023 Metastatic Breast Cancer Research Conference
  • Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting
  • Sermonix Pharmaceuticals Announces Article Comparing ‘Traditional’ to ‘Just-in-Time’ Trial Enrollment Models Is Published in JCO Clinical Cancer Informatics
  • Sermonix Pharmaceuticals Shares ASCO Poster Presentation on Longer Patient Follow-up Results for ELAINE-2 Study in ESR1-mutated Metastatic Breast Cancer
  • Sermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023

Recent Comments

    Archives

    • September 2023
    • June 2023
    • May 2023
    • March 2023
    • February 2023
    • December 2022
    • November 2022
    • September 2022
    • August 2022
    • June 2022
    • April 2022
    • February 2022
    • December 2021
    • November 2021
    • June 2021
    • May 2021
    • April 2021
    • January 2021
    • December 2020
    • October 2020
    • September 2020
    • July 2020
    • June 2020
    • December 2019
    • September 2019
    • June 2019
    • May 2019
    • April 2019
    • March 2019

    Categories

    • News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    © Sermonix Pharmaceuticals